4,458
Views
19
CrossRef citations to date
0
Altmetric
Review

Clinical development of valbenazine for tics associated with Tourette syndrome

, , , , &
Pages 393-404 | Received 12 Feb 2021, Accepted 02 Mar 2021, Published online: 01 Apr 2021

Figures & data

Table 1. Valbenazine studies in Tourette syndrome

Figure 1. Change from baseline in YGTSS TTS by visit and treatment group in double-blind, placebo-controlled studies (primary outcome)

*P< 0.05, **P< 0.01 for valbenazine versus placebo. Y GTSS TTS, Yale Global Tic Severity Scale Total Tic Score. (a) T-Forward (b) T-Force GREEN (c) T-Force GOLD.
Figure 1. Change from baseline in YGTSS TTS by visit and treatment group in double-blind, placebo-controlled studies (primary outcome)

Table 2. Primary and select additional efficacy outcomes in double-blind, placebo-controlled studies

Table 3. Treatment-emergent adverse events in double-blind, placebo-controlled studies

Figure 2. Secondary/exploratory efficacy outcomes by visit and treatment group in T-Force GOLD

*P< 0.05, **P< 0.01, ***P< 0.001 for valbenazine versus placebo. CGI-Tics-Severity, Clinical Global Impression of Tics-Severity; CGI-TS-Improvement, Clinical Global Impression of Change-Tourette Syndrome-Improvement. (a) Change from Baseline in CGI-Tics-Severity (b) CGI-TS-Improvement Score.
Figure 2. Secondary/exploratory efficacy outcomes by visit and treatment group in T-Force GOLD

Figure 3. Change from baseline in YGTSS TTS by visit in 24-week, open-label, extension studies

YGTSS TTS, Yale Global Tic Severity Scale Total Tic Score. (a) T-Fusion (b) T-Force GOLD+.
Figure 3. Change from baseline in YGTSS TTS by visit in 24-week, open-label, extension studies
Supplemental material

Supplemental Material

Download MS Word (59.3 KB)

Data availability statement

The datasets generated during and/or analyzed during the current study are not publicly available due to valbenazine being a product that has not been approved for the treatment of patients with Tourette syndrome but available from the corresponding author on reasonable request.